Quantcast

Latest Imatinib Stories

2009-09-08 07:40:51

Scientists at Fox Chase Cancer Center have discovered a unique method of attack that may be used to inhibit signaling enzymes called kinases, which often have a role in sustaining drug-resistant cancerous cells. They have confirmed that IPA-3, a small molecular inhibitor of a kinase called PAK1, targets the enzyme's regulatory domain, mimicking how enzymes are naturally regulated within cells.

4ad3b519ec5a6c0102100da5e23a382f
2009-08-05 09:30:00

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.

2009-06-08 07:27:59

In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market.

2009-06-07 12:36:18

In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market.

2009-05-28 08:30:00

MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June 2 in Orlando, FL.

2009-05-28 00:28:00

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer - New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen - Phase II data show potential of Glivec(R)...

2009-05-15 09:34:27

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.

2009-05-08 00:00:00

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been approved...

2009-04-15 11:07:33

U.S. and British scientists say they've identified a class of drugs that may enhance the effectiveness of medications used to treat chronic myeloid leukemia. People with chronic myeloid leukemia are usually first treated with a drug known as imatinib mesylate.

2009-03-18 17:37:00

- Estimated one-year, recurrence-free survival was 98% for Kit-positive GIST patients taking Gleevec vs.


Word of the Day
coruscant
  • Emitting flashes of light; glittering.
The word 'coruscant' comes from a Latin word meaning 'to flash' or 'to sparkle'.
Related